1 – 5 of 14
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population-based Swedish chronic myeloid leukaemia registry
(
- Contribution to journal › Article
-
Mark
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study
(
- Contribution to journal › Article
- 2019
-
Mark
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
(
- Contribution to journal › Article
- 2017
-
Mark
No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia : A population-based study in Sweden
(
- Contribution to journal › Letter
-
Mark
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register
(
- Contribution to journal › Article